For foreign biotechs, how to get the attention from wealthy Chinese investors? At the ChinaBio partnering forum held in Suzhou on Apr 26, Chinese investors offered some tips, report The Pharma Letter’s local correspondent, Wang Fangqing.
For one thing, do not assume that China has so much dumb money that Chinese investors will just pour money in everything foreign, cautioned Jonathan Wang, senior managing director at the Asia operation of the New York-based venture capital (VC) Orbimed.
“There might be some dumb money but Chinese investors are not fascinated by foreign technologies without local operations,” he said. Over the years, he added, many US and European Union-based teams came to China seeking funding, but most of them failed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze